X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (18) 18
female (17) 17
index medicus (17) 17
male (16) 16
pharmacokinetics (14) 14
adult (13) 13
pharmacology & pharmacy (11) 11
middle aged (10) 10
young adult (10) 10
adolescent (9) 9
drug therapy (9) 9
sch 530348 (8) 8
vorapaxar (8) 8
pharmacodynamics (7) 7
pharmacology (7) 7
aged (6) 6
analysis (6) 6
safety (6) 6
dosage and administration (5) 5
double-blind method (5) 5
medicine, general & internal (5) 5
par-1 (5) 5
pharmacology/toxicology (5) 5
proteins (5) 5
pyridines - pharmacokinetics (5) 5
research (5) 5
thrombin (5) 5
abridged index medicus (4) 4
aminophenols - adverse effects (4) 4
area under curve (4) 4
benzodioxoles - adverse effects (4) 4
biomedicine (4) 4
chloride channel agonists - adverse effects (4) 4
clinical trials (4) 4
conductance (4) 4
cystic fibrosis (4) 4
cystic fibrosis - drug therapy (4) 4
cystic fibrosis - genetics (4) 4
cystic fibrosis transmembrane conductance regulator - genetics (4) 4
drug combinations (4) 4
drug interactions (4) 4
drug therapy, combination (4) 4
genetic aspects (4) 4
indoles - adverse effects (4) 4
ivacaftor (4) 4
lactones - pharmacokinetics (4) 4
metabolism (4) 4
mutation (4) 4
patients (4) 4
pyridines - adverse effects (4) 4
pyridines - pharmacology (4) 4
quinolones - adverse effects (4) 4
receptor, par-1 - antagonists & inhibitors (4) 4
sweat - chemistry (4) 4
administration, oral (3) 3
aspirin (3) 3
child (3) 3
chlorides - analysis (3) 3
clopidogrel (3) 3
cross-over studies (3) 3
genotype (3) 3
lactones - blood (3) 3
lactones - pharmacology (3) 3
par‐1 (3) 3
physics (3) 3
platelet aggregation inhibitors - pharmacokinetics (3) 3
pyrazoles - administration & dosage (3) 3
pyrazoles - adverse effects (3) 3
pyridines - administration & dosage (3) 3
pyridines - blood (3) 3
pyrrolidines - administration & dosage (3) 3
pyrrolidines - adverse effects (3) 3
sweat (3) 3
alleles (2) 2
aminophenols - administration & dosage (2) 2
aminophenols - therapeutic use (2) 2
antagonist drugs (2) 2
benzodioxoles - administration & dosage (2) 2
benzodioxoles - therapeutic use (2) 2
biological availability (2) 2
calculating (2) 2
care and treatment (2) 2
chloride (2) 2
chloride channel agonists - administration & dosage (2) 2
chloride channel agonists - therapeutic use (2) 2
chloride transport (2) 2
collaboration (2) 2
computing (2) 2
confidence intervals (2) 2
counting (2) 2
cystic fibrosis transmembrane conductance regulator (2) 2
cystic fibrosis transmembrane conductance regulator - metabolism (2) 2
disease (2) 2
dose-response relationship, drug (2) 2
drug administration schedule (2) 2
efficacy (2) 2
electric digital data processing (2) 2
enzymes (2) 2
epithelial cells (2) 2
forced expiratory volume - drug effects (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 10/2018, Volume 379, Issue 17, pp. 1612 - 1620
This preclinical, phase 2 report shows that VX-445, a CFTR potentiator when administered with tezacaftor and ivacaftor, improved lung function and reduced... 
G551D MUTATION | MEDICINE, GENERAL & INTERNAL | TEZACAFTOR-IVACAFTOR | CFTR | Pyrazoles - therapeutic use | Forced Expiratory Volume - drug effects | Humans | Pyrrolidines - administration & dosage | Chloride Channel Agonists - therapeutic use | Male | Aminophenols - therapeutic use | Chloride Channel Agonists - adverse effects | Aminophenols - adverse effects | Pyrrolidines - pharmacology | Pyrrolidines - therapeutic use | Sweat - chemistry | Young Adult | Quinolones - adverse effects | Chlorides - metabolism | Quinolones - therapeutic use | Adult | Benzodioxoles - adverse effects | Female | Benzodioxoles - therapeutic use | Pyrazoles - pharmacology | Pyridines - therapeutic use | Pyridines - administration & dosage | Double-Blind Method | Genotype | Cystic Fibrosis Transmembrane Conductance Regulator - metabolism | Chlorides - analysis | Pyrazoles - administration & dosage | Indoles - adverse effects | Cystic Fibrosis - genetics | Adolescent | Alleles | Cystic Fibrosis Transmembrane Conductance Regulator - genetics | Indoles - therapeutic use | Pyridines - pharmacology | Mutation | Cystic Fibrosis - drug therapy | Drug Combinations | Cystic fibrosis | Ivacaftor | Dosage and administration | Drug therapy | Statistical analysis | Writers | Epithelial cells | Chloride transport | Recovery of function | Patients | Design | Proteins | Genotype & phenotype | Chloride | Collaboration | Conductance | Cystic fibrosis transmembrane conductance regulator | Protein transport | Sweat | Pharmaceuticals
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 18, pp. 1738 - 1748
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2018, Volume 379, Issue 17, pp. 1599 - 1611
This companion article to the VX-445 report shows that VX-659, a new CFTR potentiator, when administered with tezacaftor and ivacaftor improved lung function,... 
G551D MUTATION | MEDICINE, GENERAL & INTERNAL | IN-VITRO | CFTR POTENTIATOR | TEZACAFTOR-IVACAFTOR | Pyrazoles - therapeutic use | Forced Expiratory Volume - drug effects | Humans | Pyrrolidines - adverse effects | Chloride Channel Agonists - therapeutic use | Male | Aminophenols - therapeutic use | Chloride Channel Agonists - adverse effects | Aminophenols - adverse effects | Pyrrolidines - pharmacology | Pyrrolidines - therapeutic use | Sweat - chemistry | Young Adult | Quinolones - adverse effects | Quinolones - therapeutic use | Adult | Benzodioxoles - adverse effects | Female | Benzodioxoles - therapeutic use | Pyrazoles - adverse effects | Pyrazoles - pharmacology | Double-Blind Method | Cells, Cultured | Genotype | Cystic Fibrosis Transmembrane Conductance Regulator - metabolism | Chlorides - analysis | Indoles - adverse effects | Cystic Fibrosis - genetics | Adolescent | Alleles | Cystic Fibrosis Transmembrane Conductance Regulator - genetics | Indoles - therapeutic use | Mutation | Cystic Fibrosis - drug therapy | Drug Combinations | Cystic fibrosis | Ivacaftor | Genetic aspects | Dosage and administration | Drug therapy | Epithelial cells | Chloride transport | Clinical trials | Recovery of function | Patients | Proteins | Genotype & phenotype | Conductance | Cystic fibrosis transmembrane conductance regulator | Protein transport | Sweat | Binding sites | Genotypes
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2019, Volume 381, Issue 19, pp. 1809 - 1819
Triple treatment with elexacaftor, tezacaftor, and ivacaftor in patients with cystic fibrosis who had one Phe508del allele and a minimal-function mutation... 
TRANSMEMBRANE CONDUCTANCE REGULATOR | ADULT PATIENTS | MEDICINE, GENERAL & INTERNAL | EXACERBATIONS | FEV1 | POTENTIATOR | DECLINE | Cystic Fibrosis - physiopathology | Humans | Pyrrolidines - administration & dosage | Pyrrolidines - adverse effects | Male | Chloride Channel Agonists - adverse effects | Benzodioxoles - administration & dosage | Aminophenols - adverse effects | Indoles - administration & dosage | Forced Expiratory Volume | Sweat - chemistry | Young Adult | Pyridines - adverse effects | Quinolones - adverse effects | Adult | Benzodioxoles - adverse effects | Female | Child | Pyrazoles - adverse effects | Pyridines - administration & dosage | Double-Blind Method | Genotype | Chlorides - analysis | Pyrazoles - administration & dosage | Quinolones - administration & dosage | Indoles - adverse effects | Chloride Channel Agonists - administration & dosage | Cystic Fibrosis - genetics | Adolescent | Cystic Fibrosis Transmembrane Conductance Regulator - genetics | Mutation | Aminophenols - administration & dosage | Cystic Fibrosis - drug therapy | Drug Combinations | Cystic fibrosis | Ivacaftor | Genetic aspects | Drug therapy | Patient outcomes | Statistical analysis | Stock options | Clinical trials | Patients | Clinical outcomes | Quality of life | Proteins | Collaboration | Conductance | Genotypes | Pharmaceuticals
Journal Article
ISSN 1477-9226, 4/2019, Volume 48, Issue 17, pp. 5735 - 574
At present, though calcium (Ca) reagents with high calcium contents are widely synthesized, their wide application is limited due to their low absorption rates... 
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 3/2012, Volume 68, Issue 3, pp. 291 - 300
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 3/2010, Volume 65, Issue 4, pp. 727 - 734
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 5/2011, Volume 67, Issue 5, pp. 483 - 492
Journal Article
The Lancet (British edition), ISSN 0140-6736, 11/2019, Volume 394, Issue 10212, pp. 1940 - 1948
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators correct the basic defect caused by CFTR mutations. Improvements in health outcomes have... 
Double-Blind Method | Humans | yes | Pyridines/administration & dosage | Male | Pyrazoles/administration & dosage | Indoles/administration & dosage | Aminophenols/administration & dosage | Cystic Fibrosis Transmembrane Conductance Regulator/genetics | Cystic Fibrosis/drug therapy | Quinolones/administration & dosage | Adolescent | Sweat/chemistry | Female | Benzodioxoles/administration & dosage | Chloride Channel Agonists/administration & dosage | Drug Therapy, Combination | Child | Pyrrolidines/administration & dosage | MEDICINE, GENERAL & INTERNAL | GUIDELINES | Pyrrolidines - administration & dosage | Pyrrolidines - adverse effects | Chloride Channel Agonists - adverse effects | Benzodioxoles - administration & dosage | Aminophenols - adverse effects | Indoles - administration & dosage | Sweat - chemistry | Pyridines - adverse effects | Quinolones - adverse effects | Benzodioxoles - adverse effects | Pyrazoles - adverse effects | Pyridines - administration & dosage | Pyrazoles - administration & dosage | Quinolones - administration & dosage | Indoles - adverse effects | Chloride Channel Agonists - administration & dosage | Cystic Fibrosis - genetics | Cystic Fibrosis Transmembrane Conductance Regulator - genetics | Aminophenols - administration & dosage | Cystic Fibrosis - drug therapy | Clinical trials | Cystic fibrosis | Ivacaftor | Genetic aspects | Infections | Modulators | Defects | Quality of life | Resistance | Proteins | Randomization | Chloride | Chlorides | Fibrosis | Conductance | Mutation | Safety | Sweat | Active control
Journal Article
ACS Applied Materials & Interfaces, ISSN 1944-8244, 05/2018, Volume 10, Issue 21, pp. 18082 - 18092
Poor water resistance and nongreen synthesis remain great challenges for commercial narrow red-emitting phosphor A2MF6:Mn4+ (A = alkali metal ion; M = Si, Ge,... 
Research | white LEDs | composite structure | fluoride phosphor | green synthesis | water-resistant | HIGH-PERFORMANCE | MATERIALS SCIENCE, MULTIDISCIPLINARY | OPTICAL-PROPERTIES | NANOSCIENCE & NANOTECHNOLOGY | HIGH THERMAL-STABILITY | QUANTUM DOTS | LIGHT-EMITTING-DIODES | MN4 | PHOTOLUMINESCENCE PROPERTIES | SITE OCCUPANCY | WARM WLEDS | EFFICIENT
Journal Article